IDH1 and central nervous system cancer: The results indicated that MD2 expression (univariate hazard ratio (HR): 0.6, p = 1.4e-07; multivariate HR: 0.8, p = 4.2e-02), 1p/19q codeletion (univariate HR:0.3, p = 1.2e-12; multivariate HR: 0.4, p = 1.4e-05) and IDH1 mutation (univariate HR:0.3, p < 2e-16; multivariate HR: 0.5, p = 5.2e-07) could serve as independent protectable variances for gliomas, and WHO grade (univariate HR:2.8, p < 2.6e-16; multivariate HR: 2.8, p = 2.1e-34) and age (univariate HR:1.7, p = 1.2e-06; multivariate HR: 1.4, p = 8.4e-03) could be risk factors (Figure 4A).